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Signaling pathways activated by daunorubicin
Guy Laurent and Jean-Pierre Jaffre ´zou
The anthracycline daunorubicin is widely
used in the treatment of acute nonlympho-
cytic leukemia. The drug has, of course,
been the object of intense basic research,
as well as preclinical and clinical study. As
reviewed in this article, evidence stemming
fromthisresearchclearlydemonstratesthat
cellresponsetodaunorubicinishighlyregu-
lated by multiple signaling events, including
a sphingomyelinase-initiated sphingomy-
elin-ceramidepathway,mitogen-activatedki-
nase and stress-activated protein/c-Jun N-
terminal kinase activation, transcription
factors such as nuclear factor kB, as well as
the Fas/Fas-ligand system. These pathways
are themselves inﬂuenced by a number of
lipidproducts(diacylglycerol,sphingosine-1
phosphate, and glucosyl ceramide), reac-
tive oxygen species, oncogenes (such as
the tumor suppressor gene p53), protein
kinases (protein kinase C and phospho-
inositide-3 kinase), and external stimuli
(hematopoietic growth factors and the
extracellular matrix). In light of the com-
plexity and diversity of these observa-
tions, a comprehensive review has been
attempted toward the understanding of
their individual implication (and regula-
tion) in daunorubicin-induced signaling.
(Blood. 2001;98:913-924)
© 2001 by TheAmerican Society of Hematology
Introduction
The anthracycline daunorubicin (DNR) is one of the major antitumor
agents widely used in the treatment of acute myeloid leukemias
(AMLs). Cytotoxicity mediated by DNR is generally thought to be the
result of drug-induced damage to DNA. This damage is mediated by
quinone-generated redox activity, intercalation-induced distortion of the
double helix, or stabilization of the cleavable complex formed between
DNAandtopoisomeraseII.1However,howandwhysucheventsshould
bring about cell death remains unclear, especially when one considers
that DNA interaction may not be a prerequisite for anthracycline
cytotoxicity.2-5 Hence, the exploration and understanding of the process
of apoptosis has forced a reconsideration of the mechanisms whereby
myeloidleukemiacellsrespondtoDNR.Inthiscontext,wehaveshown
that, within a narrow concentration range (0.2-1 mM), DNR can trigger
apoptosis in the monocytic U937 or the myelocytic HL-60 AML cells
but not in the immature (CD 341) KG1a, KG1, or HELcells,6 the latter
being more resistant to DNR than the former.7 These results suggested
thatDNRtriggersapoptoticsignalsindrug-sensitiveAMLcellsandthat
inhibition of these signals may contribute to drug resistance and, for
example, to the inherent resistance of immature AML cells. For this
reason, others and we have investigated the mechanism by which DNR
activates apoptosis in DNR-sensitive AMLcells.
Implication of sphingomyelin metabolism
in DNR-induced apoptosis
DNR activates the sphingomyelin cycle
in sensitive leukemic cells
In the early 1990s, a number of studies provided growing evidence
that sphingomyelin breakdown products (ie, ceramide [CER] and
phosphorylcholine) could play an important role in mediating the
action of cytokines, including tumor necrosis factor a (TNFa) and
interferon. For example, Obeid et al8 were the ﬁrst to report that
TNFa could stimulate a neutral sphingomyelinase (N-SMase)
responsible for sphingomyelin hydrolysis and subsequent genera-
tion of CER in U937 cells and that C2-CER, a synthetic cell-
permeable CER analog, induced apoptosis in these cells. These
results strongly supported the implication of the sphingomyelin-
CER pathway in apoptosis induced byTNFa and, perhaps, by other
cytotoxic molecules. In further studies, Haimovitz-Friedmann et al9
proposed the involvement of the sphingomyelin-CER pathway in
apoptosis induced by g-radiation in bovine endothelial cells.
On the basis of those studies, our group investigated the role of
the sphingomyelin-CER pathway in DNR-induced apoptosis. DNR
exposure at concentrations that induced apoptosis (0.5-1 mM)
stimulated early (5-10 minutes) sphingomyelin cycle (hydrolysis
and resynthesis) and subsequent CER generation in both U937 and
HL-60 cells. The concentration of endogenous CER generated
(;10 mM, estimated by cell volume) is clearly sufﬁcient to induce
apoptosis.8 Because these cells exhibit a mutated or deleted form of
p53, it appears that CER operated through a p53-independant
mechanism. Further studies have shown that DNR induced sphin-
gomyelin hydrolysis associated with the stimulation of N-SMase,
whereas acidic SMase did not appear to be involved.10 Moreover,
we have recently reported that DNR induced sphingomyelin cycle,
CER generation, and apoptosis in Epstein-Barr virus–transformed
lymphoblastoid cell lines established from patients with Niemann-
Pick disease, a genetic disorder characterized by the lack of acidic
SMase activity.11 These results suggest that acidic SMase is
dispensable for DNR-induced sphingomyelin hydrolysis.
In another study, Bose et al12 have proposed that DNR may
induce CER accumulation because of enhanced de novo synthesis
through CER synthase stimulation, a mechanism that has also been
suggested for TNFa-induced cell death in nonhematopoietic cell
From the INSERM E9910, Institut Claudius Re ´gaud, Toulouse, France; and the
Service d’He ´matologie, Centre Hospitalier Universitaire Purpan, Toulouse,
France.
Submitted November 27, 2000; acceptedApril 5, 2001.
Supported by la Ligue Nationale Contre le Cancer and les Comite ´s
De ´partementaux du Gers, de l’Aveyron, du Lot et de la Haute-Garonne (J.P.J.),
in part by l’Association pour la Recherche sur le Cancer grant 5526 (G.L.), by
La Faculte ´d eM e ´decine Toulouse-Rangueil (G.L.), and by le Centre National
d’Etudes Spaciales (J.P.J.).
Reprints: Guy Laurent, INSERM E9910, Institut Claudius Re ´gaud, 20 rue du
Pont St Pierre, 31052 Toulouse, France; e-mail: laurent@icr.fnclcc.fr.
© 2001 by TheAmerican Society of Hematology
913 BLOOD, 15AUGUST 2001z VOLUME 98, NUMBER 4
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From death.13,14 However, it should be noted that, in the study by Bose et
al,12 cells were treated with very high DNR doses, whereas, at
clinically relevant drug concentrations, we were unable to detect
CER synthase stimulation.10 The fact that sphingomyelin hydroly-
sis occurred within 5 to 10 minutes after drug exposure and
apoptosis was not detected before 4 to 6 hours raised some
controversies about the implication of the sphingomyelin cycle in
DNR apoptosis. Therefore, we have carefully examined the
inﬂuence of DNR on sphingomyelin metabolism over a longer
period of time (0-12 hours).
In this study, we have found that DNR exposure resulted in at
least 4 sphingomyelin cycles (hydrolysis and resynthesis) with
concomitant (4 cycles) CER production within the ﬁrst 4 hours,
after which poly(ADP-ribose) polymerase cleavage, DNA ladder-
ing,andapoptosis-associatedmorphologicchangesoccurred.More-
over, the successive waves of CER production were not inﬂuenced
by fumonisin B1, a potent and speciﬁc CER synthase inhibitor.15
These results conﬁrmed that de novo CER synthase plays little if
any role in DNR-induced CER signaling. The fact that DNR
induced several peaks of CER production suggested that sphingo-
myelin hydrolysis products (ie, CER or phosphorylcholine) might
reactivate N-SMase. In fact, we have found that cell-permeant CER
may indeed stimulate N-SMase, sphingomyelin hydrolysis, and
endogenous CER production, suggesting that CER may enhance its
own production through feedback control of N-SMase.15 There-
fore, one can speculate that DNR activates a single sphingomyelin
cycle that is sufﬁcient for inducing CER autoproduction and that
these repeated CER-mediated apoptotic signals are perhaps needed
for maintaining an apoptotic (cell suicide) signaling pressure
overcoming latent cell survival mechanisms. Finally, it is notewor-
thy that DNR-induced topoisomerase II cleavable complexes have
not been described in the literature under these conditions (1 mM
DNR treatment for 4 hours); of course this does not demonstrate
unambiguously that DNR interaction with DNA, or more speciﬁ-
cally with topoisomerase II, is not requisite for apoptosis signaling
because it can be argued that present experimental procedures lack
sensitivity in detecting minute amounts of DNR-topoisomerase-
DNAcomplexes.
CER targets
The emergence of CER as an important mediator of cell death
induced by cytotoxic molecules has stimulated an extensive search
for downstream targets involved in CER-mediated apoptosis. In
fact, CER was found to activate a large variety of signaling
proteins, including Raf-1, extracellular-regulated kinases (ERKs),
a CER-activated protein phosphatase, as well as stress-activated
protein/c-Jun N-terminal kinase (SAPK/JNK). By using dominant-
negative mutants, Verheij et al16 elegantly demonstrated that the
MEKK1-SEK1-JNK cascade is one of the major components of
CER-mediated apoptosis. This ﬁnding is consistent with another
study which showed that c-Jun activation is required for CER-
mediated apoptosis.17 Further studies have supported the function
of JNK in the initiation of programmed cell death. For example, it
was shown that overexpression of MEKK1 or ASK1, 2 potent and
speciﬁc in situ activators of SEK1 and JNKs, had lethal effect on
ﬁbroblasts.18-20 Because DNR triggers both CER production and
apoptosis, it was expected that this drug may also activate JNK
signaling. In fact, we and others have reported that both DNR and
doxorubicin, in a dose-dependent manner, increased JNK1 tyrosine
phosphorylation, stimulated JNK1 enzymatic activity, and en-
hanced DNA binding activity of the transcription factor activated
protein-1 (AP-1).21-23 Anthracyclines are not the unique antitumor
agents that activate the JNK/c-Jun pathway. Indeed, other geno-
toxic agents such as UV,24 ionizing radiation,25-27 alkylating
agents,25 etoposide,21 or cytosine arabinoside28 as well as nongeno-
toxic agents such as microtubule poisons29,30 also activate JNK.
These observations suggest a general function for JNK in mediat-
ing cell death induced by antitumor agents (see Kyriakis and
Avruch for review31). Therefore, it appears that, in leukemic-
sensitive cells, DNR activates a complex signaling cascade that
consists of repeated sphingomyelin cycles followed by several
waves of CER production; this second messenger, in turn, activates
a common downstream cell death effector-mediated pathway that
involves JNK stimulation and c-Jun/AP-1 activation.
Regulation of CER production
CER production is limited by both N-SMase activity and the
magnitude of sphingomyelin pool disposable for hydrolysis. Previ-
ous studies have shown that N-SMase activity is strongly inﬂu-
enced by protein kinase C (PKC) activity. For example, we have
reported that phorbol ester– or phosphatidylserine-induced PKC
stimulation resulted in the inhibition of N-SMase stimulation,
sphingomyelin hydrolysis, CER production, and apoptosis induced
by DNR in U937 cells.32 Conversely, PKC inhibitors were found to
stimulate N-SMase.33 The amount of hydrolyzable sphingomyelin
is another candidate for regulating CER production. Indeed, it has
been reported that, whereas sphingomyelin is preferentially distrib-
uted within the outer leaﬂet of the plasma membrane (sphingomy-
elin transverse asymmetry), the sphingomyelin pool disposable for
hydrolysis consists primarily in the sphingomyelin component that
is associated to the plasma membrane inner leaﬂet.34 Thus, it is
conceivable that reduction of hydrolyzable sphingomyelin pool
because of altered transverse asymmetry may result in reduced
CER production. In 2 studies, we have reported that, in KG1aAML
cells, which are naturally resistant to DNR,7 mitoxantrone,35 and
TNFa,36 the inner leaﬂet-associated sphingomyelin pool was
greatly reduced, compared with the sensitive U937 cells, whereas
KG1a and U937 cells exhibited similar total sphingomyelin
amount. Interestingly, in the resistant cells, cytotoxic effectors such
as TNFa,36 DNR, and mitoxantrone (A Bettaie ¨b et al, unpublished
results, July 1997) failed to induce sphingomyelin hydrolysis, CER
generation, and apoptosis. Thus, it is possible that, in some AML
cells, the activation of yet undeﬁned sphingomyelin translocases
results not only in modiﬁcation of sphingomyelin transverse
asymmetry but also in reduced sphingomyelin hydrolyzable pool,
decreased CER production, and inhibition of apoptosis.37 Conﬁrm-
ing this hypothesis, it has recently been shown that the CER
generated from the plasma membrane sphingomyelin gains access
to a SMase because of phospholipid scrambling.38
Regulation of CER metabolism
Intracellular CER concentration results from the equilibrium
between CER production and CER metabolism. CER metabolism
also plays an important role in regulating intracellular CER
concentration and therefore DNR cytotoxicity. Theoretically, CER
produced by DNR may enter into 3 distinct metabolic pathways
that all result in decreasing intracellular CER levels.
First, CER can be transferred to a phosphorylcholine group to
generatesphingomyelin(anddiacylglycerol[DAG])onsphingomy-
elin synthase stimulation. It is likely that this metabolic pathway is
activatedforsphingomyelinresynthesisaftersphingomyelinhydro-
lysis during the sphingomyelin cycle. This enzyme therefore has
the important ability to directly regulate, in opposite directions,
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biological potential of sphingomyelin synthase, very little is known
about location, distribution, and regulation of this enzyme.40
Whether sphingomyelin synthase plays a role in DNR-induced
cytotoxicity remains to be investigated.
Second, on ceramidase stimulation, CER can be catabolized
into sphingosine that, in turn, can be converted into sphingosine-1-
phosphate through sphingosine-1-kinase. In a recent study, we have
reported that DNR induced CER production and apoptosis in cells
derived from Farber disease, which are genetically deﬁcient for
lysosomal ceramidase, the major component of cellular ceramidase
activity.41 Although we cannot totally exclude the implication of
extralysosomal ceramidases,42 this result suggests that sphingosine
plays little if any role in DNR-induced apoptosis. However, from
studies performed by Cuvillier et al,43,44 sphingosine-1-phosphate
has emerged as one of the most potent regulators of apoptosis.
Indeed, sphingosine-1-phosphate inhibits apoptosis induced by
CERandothereffectors.43,44Themechanismbywhichsphingosine-
1-phosphate interferes with CER-induced apoptotic signaling is not
fully understood. However, it has been reported that sphingosine-1-
phosphate inhibits CER-induced JNK stimulation and caspase
activities.44,45Therefore,sphingosine-1-phosphateandsphingosine-
1-kinase might play an important role in regulating DNR-induced
apoptosis. In fact, it has been demonstrated that sphingosine-1-
phosphate inhibits doxorubicin-induced apoptosis.46 From these
studies, one can speculate that sphingosine-1-kinase stimulation
may contribute to DNR resistance. Because sphingosine-1-kinase
is potently stimulated by PKC, it is possible that sphingosine-1-
phosphate overproduction represents another mechanism by which
PKC exerts its protective function in DNR-treated cells.
Third, CER can be transformed to glucosylceramide by a
glucosylceramide synthase. Previous reports have indicated that
glucosylceramide has no cytotoxic property or may even stimulate
cell proliferation47 and that glucosylceramide synthase inhibitors
have been found to display some antitumor activity.48,49 These
results suggest that glucosylceramide synthase plays an important
role in cellular protection. Indeed, it has been described that cells
transduced by glucosylceramide synthase gene were highly resis-
tant to anthracyclines50 and that enzyme activity was signiﬁcantly
boosted in multidrug-resistant (MDR) cells.51 Conversely, transfec-
tion of glucosylceramide synthase antisense reverses adriamycin
resistance.52 DNR triggers the sphingomyelin cycle in MDR cells
when used at high doses.53 Therefore, one can speculate that in
DNR-treated MDR cells CER originated from sphingomyelin
hydrolysis is rapidly converted to glucosylceramide because of
glucosylceramide synthase overactivity.54,55 If this speculation is
the case, glucosylceramide synthase appears as an attractive target
for MDR reversal. In fact, inhibition of CER glycosylation
pathway increases MDR cell sensitivity to cytotoxics.56 The same
group has reported that most MDR modulators, including cyclo-
sporin A, tamoxifen, and verapamil, are potent glucosylceramide
synthase inhibitors, whereas the cyclosporin A analogue PSC 833
(Valspodar), a clinically used potent MDR reversal agent, increases
intracellularCERconcentrationbystimulatingCERsynthase.51,57,58
These results suggest that those agents may exert their chemosensi-
tizing effect not only through their P-glycoprotein binding capacity,
as previously postulated, but also by facilitating CER accumula-
tion. However, the mechanism by which CER modulates anthra-
cycline-induced cytotoxicity in MDR cells remains to be deter-
mined. For example, there is no evidence that CER interferes
with P-glycoprotein function or intracellular drug distribution in
MDR cells.59
Regulation of CER apoptotic signaling pathway
The sphingomyelin-CER pathway appears to be efﬁciently regu-
lated downstream of CER generation. Bcl-2 inhibits apoptosis
induced by DNR without interfering with DNR-induced sphingo-
myelin cycle activation.60 This result is consistent with previous
studies which have shown that Bcl-2 inhibits apoptosis induced by
cell-permeant CER.61 PKC is also a potent regulator of CER-
induced apoptosis. Indeed, previous studies not only showed that
PKC activators, including phorbol esters and DAG, could inhibit
the ability of cell-permeant CER to induce apoptosis but also that
PKC inhibitors enhanced CER-induced apoptosis.9,32,62,63 There-
fore, PKC appears as a critical regulator of the sphingomyelin-CER
pathway because it operates both upstream and downstream of
CER production. This ﬁnding may have important implications in
our understanding of AML-cell drug resistance. Indeed, a large
varietyofhematopoieticgrowthfactors(HGFs),includinginterleu-
kin 3 (IL-3), granulocyte-macrophage colony-stimulating factor
(GM-CSF), or basic ﬁbroblast growth factor, were found to
stimulate PKC activity through phosphatidylinositol or phosphati-
dylcholine hydrolysis and subsequent DAG production.64 Thus, it
is conceivable that autocrine production of HGFs by leukemic cells
may result in DNR-induced sphingomyelin-CER pathway inhibi-
tion and thereby contribute to reduce DNR cytotoxicity in AML.
The fact that HGFs were found to inhibit DNR-induced apopto-
sis,65,66 as well as the chemosensitizing effect of PKC inhibitors on
fresh AML cell progenitors cultured in the presence of HGFs,67
supports this hypothesis. Moreover, we have recently found that
Kit signaling, activated either by its natural ligand (stem cell factor)
or by modiﬁcation of its intracellular domain, inhibits DNR-
inducedSMasestimulation,CERproduction,andapoptosisthrough
a PKC-dependent mechanism.68
Implication of radical oxygen species
in DNR-induced apoptosis
During the treatment of the cells with anthracyclines, nicotin-
amide adenine dinucleotide phosphate (NADPH)–dependent
ﬂavin reductase reduces the drug to a semiquinone radical,
which can donate its free electron to molecular oxygen and
generate the superoxide radical (O2
c). At neutral pH, the main
reaction of O2
c is a relatively slow spontaneous dismutation to
H2O2 and O2, but this reaction can be accelerated by superoxide
dismutase. Superoxide anion and hydrogen peroxide may inter-
act (with metal ions such as iron or copper as catalyst), by the
Haber-Weiss reaction to generate hydroxyl radicals (cOH). By
employing electron spin resonance together with a spin-trap
such as DMPO (5,5-dimethyl-1-pyrroline N-oxide), anthracy-
cline-induced cOH has been detected in several types of cancer
cells (see Sinha and Mimmaugh for review69). Electron spin
resonance radicals have also been detected in intact erythrocytes
treated with DNR.70 This result suggests that anthracycline-
induced free radical production may occur independently from
the interaction of the drug with internal membrane or even
DNA. In addition, it has been demonstrated that all forms of
radical oxygen species (ROS) may also be generated through the
direct interaction of anthracyclines with cell membranes and
subsequent lipid peroxidation.71 Although there is strong evi-
dence that ROS plays a role in the cytotoxicity of anthracy-
clines, the mechanism by which ROS inﬂuences cell viability
remains unclear.
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inhibited by ROS scavengers such as pyrrolidine dithiocarbamate
and N-acetylcystein, a thiol antioxidant and a glutathione precur-
sor, and was enhanced by buthionine-sulfoximine, which depletes
the glutathione store.6 These results encouraged us to investigate
the role of ROS in the DNR-stimulated sphingomyelin-CER-JNK
apoptotic pathway. Indeed, the level of endogenous H2O2 generated
is comparable to that of a cell treated with 12 mMH 2O2. In fact,
further studies showed that pretreatment with N-acetylcystein
abrogated DNR-induced N-SMase stimulation, sphingomyelin
hydrolysis, and CER generation induced by DNR, evoking a role
for ROS in N-SMase regulation.23 This hypothesis is supported by
2 other studies which showed that H2O2 stimulates sphingomyelin
hydrolysis and CER generation and that N-acetylcystein and
pyrrolidine dithiocarbamate were potent inhibitors of TNFa-
inducedsphingomyelindegradationtoCER.72,73Thus,itisconceiv-
able that ROS originated from the NADPH-dependent DNR
reduction contributes to N-SMase stimulation and subsequent CER
generation. However, the mechanism by which ROS regulates
N-SMase activity is not known.
Other studies have demonstrated that ROS also plays a role in
CER-induced apoptosis. Indeed, permeant CER induced early and
transient (5-10 minutes) H2O2 production, followed by a second
wave of H2O2 detected at 1 to 3 hours that originated from
mitochondrial oxidative metabolism disturbances. Furthermore,
N-acetylcystein inhibited H2O2 production, JNK activation, AP-1
activation, and apoptosis induced by CER.23,74,75 These results
suggest that ROS plays an important role in the sphingomyelin-
CER apoptotic pathway triggered by DNR at 2 different levels:
upstream CER generation by stimulating N-SMase activity and
downstream CER activity by mediating CER-induced JNK activa-
tion. The results also suggest a novel function of cytosolic-
originated ROS in the cytotoxicity mechanism of anthracyclines.
Thus,antioxidants,includingsuperoxidedismutase,catalase,gluta-
thione peroxidase, or thioredoxin, may inﬂuence DNR-induced
cytotoxicity.
However, the fact that antioxidants inhibit apoptosis induced
by chemotherapeutic drugs that have not been documented to
stimulate the sphingomyelin cycle (ie, actinomycin D, campto-
thecin, etoposide, and melphalan),76 raises the possibility that
ROS interferes with other apoptotic pathways in DNR-treated
cells. Furthermore, there is mounting evidence that ROS
activates or mediates many other signaling pathways, which can
contribute more generally to the cellular response to DNR. For
example, ROS modulates both PKC77-79 and tyrosine kinase
activities,80-85 contributes to cell cycle block,86 stimulates Raf-1/
ERK mitogen-activated protein (MAP) kinases,84,87 and triggers
activation of critical transcription factors, including nuclear
factor-kB (NF-kB) (see Baeuerle and Henkel for review88), a
negative regulator of DNR-induced apoptosis,89 which we will
discuss later. These results suggest a complex role for ROS,
which may mediate both cell death and survival signaling
pathways, and thereby could play a major role in orientating the
cellular response to genotoxic insult.
Implication of phosphatidylcholine
metabolism in DNR-induced apoptosis
Anthracyclines, as other genotoxic agents including alkylating
agents and ionizing radiation, have been shown to increase cellular
DAG levels and PKC activity.90 However, the source of DAG as
well as its functional role in the cellular response to the drug were
not determined. In another study, we have reported that, in U937
cells, DNR (and mitoxantrone) transiently stimulated concurrently
with CER generation both DAG and phosphorylcholine production
by phospholipase C hydrolysis of phosphatidylcholine. Moreover,
pretreatment of cells with the xanthogenate compound D609, a
potent inhibitor of phosphatidylcholine hydrolysis, led to a sus-
tained increase in CER levels. This result suggests that DNR may
trigger in parallel both cell death (CER) and survival (DAG and
phosphorylcholine) mediators and that, in sensitive leukemic cells,
CER overrides the protective function of DAG and phosphorylcho-
line.91 These results support the notion that reciprocal regulation
through DAG and CER may be implicated in the regulation of
apoptosis.92Themechanismbywhichphosphatidylcholine-derived
DAG inﬂuenced intracellular CER concentration in DNR-treated
cellsisnotyetcharacterized;however,becausephosphatidylcholine-
derived DAG did not appear to inﬂuence N-SMase stimulation, it is
conceivable that DAG enhanced CER metabolism by facilitating
sphingomyelinsynthesis.Furthermore,ithasbeendocumentedthat
phosphatidylcholine-derived DAG binds and stimulates Raf-1
kinase activity93,94 and, through Raf-1, may activate the MEK1/
ERK classical MAP kinase module, a negative regulator of
apoptosisinducedbyvariousstresses.84,87,95-97Phosphatidylcholine-
derived DAG has been found to stimulate some PKC isoforms such
as PKC z or i “atypical” isoforms that have been involved in cell
proliferation and/or survival.98-100 In fact, we have recently ob-
served that DNR stimulates Raf-1, ERK1, and PKC z activities
through a D609-inhibitable mechanism (V Mansat-De Mas, I Plo,
C Bezombes, et al; unpublished results, November 2000). Alto-
gether these ﬁndings suggest that, in DNR-treated cells, phosphati-
dylcholine-derived DAG potentially operates by modulating the
activity of diverse serine kinases and thereby contributes to reduce
drugcytotoxicity.Regardlessofthemechanismbywhichphosphati-
dylcholine-derived DAG exerts its protective function, this result
may have some clinical implications. Indeed, it has been demon-
strated that p21Ras or src oncogenes, as well as cytokines,
including IL-3, GM-CSF, and TNFa, are potent activators of
phosphatidylcholine hydrolysis and thereby may induce sustained
DAG production.101-104 Therefore, it is conceivable that, in some
AML cells, expression of some oncogenic products, as well as
stimulation by cytokines, may severely impair DNR-induced
apoptosis through a phosphatidylcholine-derived DAG-depen-
dent mechanism.
Implication of the phosphoinositide 3-kinase
in DNR-induced apoptosis
Among other enzymes that are involved in signal transduction
pathways, phosphoinositide 3-kinase (PI3K) plays an important
role. PI3Ks are a family of enzymes that catalyze the phosphoryla-
tion of inositol lipids at the D3 position of the inositol ring,
generating new intracellular second messengers (see Franke et al105
for review). The lipid products of PI3K are phosphatidylinositol-3-
phosphate (PtdIns-3-P), phosphatidylinositol-3,4-biphosphate
(PtdIns-3,4-P2), and phosphatidylinositol-3,4,5-triphosphate
(PtdIns-3,4,5-P3). PtdIns-3,4-P2 and PtdIns-3,4,5-P3 have been
demonstrated to interact with a large variety of downstream effec-
tors, including serine-threonine kinase Akt,106 calcium-insensitive
PKCd, e, and h isoforms,107 as well as atypical PKC z isoform108
or phospholipase C.109 The use of PI3K inhibitors, wortmannin and
LY294002, and PI3K mutants has demonstrated a role for PI3K in
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tion.110,111 For this reason, we have investigated the implication of
PI3K in the cellular response to DNR in U937 cells. In fact, DNR
induced a 2-fold increase in PI3K activity with transient accumu-
lation of PtdIns-3,4-P2 and PtdIns-3,4,5-P3, and Akt activation.
Wortmannin and LY294002 also accelerated DNR-induced apo-
ptosis, suggesting that PI3K stimulation may contribute to cell
survival.112 However, as already described earlier for phospho-
lipase C activation by DNR, the stimulation of PI3K integrates into
a futile response of the cells to the drug and only slightly affect
DNR cytotoxicity. However, according to a recent report, it
appears that PI3K may play a much more prominent protective
effect against doxorubicin-induced apoptosis.113 Moreover, these
results suggest that potent and sustained PI3K activation induced
by oncogenic products, such as Ras114 or BCR-ABL115-117,o rb y
mutated forms of HGF receptors, such as Flt3118, may result in
signiﬁcant protection toward DNR and perhaps other antileukemic
agents. The mechanism by which PI3K or PI3K products interfere
with DNR-induced apoptosis is still under investigation. However,
from other studies, one can speculate that the PI3K protective
function involves Akt-mediated phosphorylation of Bcl-2 fam-
ily,119 inhibition of caspase activity,120,121 or stimulation of PKC
isoform activities.107,108 Moreover, it has been reported that cell-
permeant CER decreasesAkt activity,122 suggesting possible cross-
talk between sphingomyelin-CER and PI3K-Akt pathways in
DNR-treated cells.
Implication of NF-kB activation
in DNR-induced apoptosis
NF-kB is a member of the mammalian Rel family of transcriptional
activators that plays a central role in the regulation of immune
responses, embryogenesis, and hematopoiesis. NF-kB is a het-
erodimer consisting of the 50-kD (p50) and 65-kD (p65) subunits
that, in its inactive state, is located in the cytoplasm bound to an
inhibitory protein (IkBa). On activation, NF-kB disassociates from
IkBa, translocates to the nucleus, and binds to DNAto regulate the
expression of many genes.88 By using electrophoretic mobility shift
assays, it has been shown that NF-kB DNA binding activity is
stimulatedbycytotoxiceffectors,includingDNA-damagingagents,
such as ionizing radiation, alkylating agents, anthracyclines, topo-
isomerase inhibitors, and cytosine arabinoside.89,123-130 However,
the fact that nongenotoxic anticancer compounds such as vinca
alkaloids and taxanes125 may also activate NF-kB suggests that
DNA damage is not necessarily needed for drug-induced NF-kB
activation. This ﬁnding could mean that these drugs share some
NF-kB–activating signaling pathways that can be generated in the
cytosol but not in the nucleus, similar to that observed in the UV
response in which NF-kB activation was clearly demonstrated to
be initiated not in the nucleus but at or near the plasma membrane
through a Src- and Ras-dependent mechanism.80 DNR-induced
NF-kB activation does not require de novo protein synthesis and
appears to be speciﬁc.125
Despite many efforts, the mechanism by which DNR activates
NF-kB is not totally understood. Because, on one hand, NF-kBi s
considered to be an oxidative stress-responsive transcription fac-
tor,88 and, on the other hand, DNR is known to generate ROS, one
could speculate that ROS could be involved in DNR-induced
NF-kB activation. However, the role of ROS was not ﬁrmly
established. Indeed, whereas the antioxidant pyrrolidine dithiocar-
bamate was found to inhibit DNR-induced NF-kB activation in
HL-60 and Jurkat T cells,124 opposite results have been reported in
a human colon carcinoma cellular model.126 Moreover, mitox-
antrone, which is unable to undergo redox cycling, was also found
to activate NF-kB in a pyrrolidine dithiocarbamate–insensitive
manner, suggesting that the inhibitory effect of pyrrolidine dithio-
carbamate could not be related to its antioxidant property.129 CER
was also a plausible candidate. Indeed, previous studies have
shown that the addition of CER induced NF-kB activation.130 In
fact, we found that the inhibition of DNR-induced SMase stimula-
tion and subsequent CER production by serine-protease inhibitors
reduces the capacity of the drug to activate NF-kB.131 However,
because of the broad speciﬁcity of these agents, the role of CER
was not totally established, and one could not exclude a CER-
independent mechanism as it has been proposed for TNFa-induced
NF-kB activation.132,133 On the basis of previous studies which
have shown that phosphorylation events are critical for NF-kB
activation,88 the role of PKC has been investigated. Also, PKC
inhibitors were found to block DNR-induced NF-kB activation,125
suggesting that DNR-triggered PKC stimulation plays an important
role in NF-kB activation. In fact, previous studies have already
suggested that PKC may act indirectly on phosphorylation and
subsequent degradation of IkB.88 More recent studies have indi-
cated that IkB phosphorylation is under control of 2 IkB kinases
(IKKa and IKKb) which phosphorylate residues 32 and 36 of
IkBa and that atypical PKC isoforms are critical regulators of the
IKK activity.134Altogether these results render those PKC isoforms
plausible candidates for mediating anthracycline-induced NF-kB
activation. Finally, one cannot rule out the role of PI3K/Akt
pathway. Indeed, it has been shown that activated Akt directly
interacts and phosphorylates IkB-kinase (IKK).135,136 Whether or
not DNR-induced PI3K/Akt pathway is involved in DNR-induced
NF-kB activation should be examined.
Previous studies have shown that NF-kB inhibits apoptosis
and/or enhances survival in a large variety of hematopoietic cells,
including B lymphocytes,137 Hodgkin disease cells,138 and CD341
bone marrow cells.139 Therefore, it was tempting to speculate that
this transcription factor provides signiﬁcant protection against
DNR-induced cytotoxicity. Such a hypothesis was supported by the
fact that NF-kB was found to play an essential role in preventing
TNFa-induced cell death.89,140,141 To address this question more
directly for DNR, Wang et al89 have used a gene construct coding
for a super-repressor form of the NF-kB inhibitor IkBa. This IkB
repressor contains mutations, which inhibit signal-induced phos-
phorylation and subsequent proteasome-mediated degradation of
IkB. This mutant protein binds to NF-kB and prevents nuclear
translocation as well as DNA binding.142,143 Using this methodol-
ogy, those investigators have shown that NF-kB inhibition resulted
in increased cytotoxic effect of DNR (and ionizing radiation) in
vitro.89 Although other studies suggest that the role of NF-kBi n
drug resistance may be a function of the cellular model, 127,128 these
results may have important clinical implications. Indeed, some
pharmacologic agents are known to inhibit cytokine-induced
NF-kB activation, including glucocorticoids, which act through
induction of IkB synthesis.144,145 Glucocorticoids are largely used
in association with anthracyclines as part of front-line therapy of
myeloma, acute lymphoid leukemia, and lymphoma. Whether or
not glucocorticoids act in synergy with anthracyclines in lymphoid
cells through a NF-kB–dependent mechanism has not been evalu-
ated. Altogether these ﬁndings provide new insights in the under-
standing of synergistic drug combinations currently used in the
clinical setting. These ﬁndings also provide a rationale for novel
chemosensitization strategies based on NF-kB pathway inhibition.
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super-repressor could result in sensitizing tumor cells in vivo to
DNR, as it has been shown for the topoisomerase I inhibitor
CPT-11.146 It is also conceivable to interfere with proximal
upstream regulators of NF-kB activation (ie, Akt or PKCz by
inhibiting IKK activation147).
The mechanism by which NF-kB contributes to apoptosis
inhibition remains uncertain. It has been suggested that NF-kBi sa
negative regulator of p53 gene expression, and it has also been
reported that p53-activating signal is partially blocked by inhibition
of NF-kB activation in DNR-treated cells.126
Role of death receptors/death ligand
and caspases
Doxorubicin, as other antitumor compounds such as methotrexate,
cisplatin, ﬂudarabine, or bleomycin as well as ionizing radiation,
was shown to enhance the expression of Fas and Fas-L on the
surface of certain leukemic or epithelial malignant cells. For this
reason, it has been proposed that doxorubicin-induced apoptosis
occurs through autocrine or paracrine induction of the Fas-
dependent pathway.148-151 In these studies, this hypothesis was
supported by 2 lines of evidence: (1) cell lines resistant to Fas were
found insensitive to anticancer drug-induced apoptosis, and (2)
doxorubicin-induced apoptosis was prevented by CD95-neutraliz-
ing antibodies. However, this issue remains highly controversial
mainly because antagonistic anti-Fas antibodies do not always
inhibit drug-induced cell death.152-154 Moreover, many cells either
naturally resistant to Fas (ie, HL-60 cells) or selected for Fas
resistance152-154 remain sensitive to doxorubicin-induced apoptosis.
Therefore, convincing evidence now exists showing that Fas/Fas-L
pathway is not a principal and necessary mechanism of anthracy-
cline-induced apoptosis.154
Other investigators have reported that in carcinoma cells
doxorubicin induced the clustering of Fas receptor and its interac-
tion with Fas-associated death domain-containing protein (FADD)
in a Fas-L–independent fashion.155This has also been described for
UV and ionizing radiation.156,157 FADD is an adapter molecule,
which is recruited to Fas cell death domain, and then binds to and
activates procaspase-8; active caspase-8, in turn, triggers activation
of a proteolytic cascade that leads through caspase-7, caspase-3,
and caspase-6 to apoptosis. Moreover, these investigators showed
that FADD overexpression facilitated drug-induced apoptosis,
whereas down-regulation of FADD by transient transfection of an
antisense construct decreased tumor cell sensitivity to the drug.155
For this reason, it has been proposed that doxorubicin-induced cell
death involves the Fas/FADD pathway without interfering with
Fas-L production and that FADD expression may signiﬁcantly
inﬂuence the cellular response to this drug. Fas clustering by
cytotoxic agents was also described for VP-16, cisplatinum, and
vinblastin155 as well as for UV radiation.157 However, the role of
FADD in doxorubicin-induced caspase activation and apoptosis
may be a function of the cellular model. Indeed, in doxorubicin-
treated Jurkat leukemic T cells, Wesselborg et al154 have shown a
correlation between doxorubicin-apoptosis and cleavage of pro-
caspase-8 to its active p18 subunit; however, the expression of a
dominant-negative FADD construct selectively abrogated Fas but
not drug-induced effects. This result suggests that caspase-8 can be
activated by doxorubicin in the absence of Fas receptor signal-
ing.154 Fas- and FADD-independent caspase-8 activation have been
observed in lymphoid cells treated with ionizing radiation.158
Altogether these results suggest that, whatever the role of FADD,
caspase-8 activation represents a critical step in the cascade
resulting in terminal proteolytic events, including caspase-3 and
caspase-6 activation responsible for the cleavage of poly(ADP-
ribose) polymerase and nuclear lamins, respectively. However,
other investigators have questioned the role of caspase-8. For
example,Villunger et al153 have reported that expression of cowpox
virus cytokine response modiﬁer A, a potent inhibitor of distinct
members of the caspase-protease family, including caspase-8,159
did not inﬂuence doxorubicin-induced apoptosis in T-acute lym-
phatic leukemia CEM cells, whereas it prevented Fas-mediated
apoptosis. Moreover, expression of FLIP (FLICE-inhibitory pro-
tein), which binds to caspase-8 and interferes with its function, was
found to have no inﬂuence on apoptosis induced by doxorubicin or
by other antileukemic compounds or by g irradiation, whereas it
abrogated Fas-mediated apoptosis in JurkatTcells.160Although the
implication of Fas system and/or Fas signaling proximal adapter
molecules including FADD or caspase-8 remains a controversial
issue, the role of caspase-3 in doxorubicin-induced apoptosis was
ﬁrmly established through different approaches, including peptide
inhibitor and antisens.161 However, the fact that these inhibitors
were effective, even if added several hours after drug treatment,
indicates that this caspase is involved in the execution and not in
the triggering phase of drug action.161 Finally, it should be pointed
out that the link, if any, between caspase signaling and CER
pathway activated by anthracyclines is not yet determined. Indeed,
previous studies have established that cytokine response modiﬁer
A–induced caspase inhibition resulted in the inhibition of CER
generation and cell death induced by cytotoxic molecules such as
TNFa162 or Fas agonist,163 suggesting a role for caspase in
controlling SMase stimulation. Whether or not caspase-mediated
proteolytic events take place upstream, CER generation in anthra-
cycline-treated cells has not been yet investigated.
Whatever the intimate mechanism by which Fas and caspases
are involved in the cellular response to anthracyclines, all these
results have important clinical implications. First, on the basis of
the stimulatory effect of anthracyclines on Fas-L production in
some tumor cells and with the demonstration that Fas-L produced
by tumor cells can kill the speciﬁc effector CTLand other activated
T cells that express Fas,164 it can be speculated that chemotherapy
may decrease cellular cytotoxicity of natural effectors and, there-
fore, may facilitate immune escape.165 Conversely, it has been
proposed that drug-induced Fas expression may result in sensitiza-
tion toward Fas-dependent cytotoxicity of cellular immune effec-
tors.166-169 Second, previous studies have shown that, whereas
short-term culture with doxorubicin enhanced Fas expression level,
prolonged exposure to the drug may result in Fas reduction or even
lack of expression, establishing an intriguing link between MDR
phenotype and Fas resistance.170 Similar results have been obtained
with mitoxantrone.171 Third, if Fas signaling molecules (or Fas
itself) play an important role in anthracycline-induced apoptosis, it
is conceivable that diminution of their expression and/or altered
capacity to form the multimolecular death-initiating signaling
complex constituted by Fas death domain, FADD, and pro-
caspase-8 may impair drug cytotoxicity. In this perspective, it is
important to note that AML cells (as well as immature progenitor
cells) are generally insensitive to Fas commitment although most
of them do express Fas, suggesting a disruption in Fas-mediated
death signaling.172-174 Therefore, it is tempting to speculate that
negative control of Fas signaling contributes not only to immune
escape but also to decreased drug cytotoxicity in leukemia cells.
Finally, one should not disregard the emerging evidence that
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scribed to increase death receptors such as DR5 for TRAIL/Apo-2
ligand in leukemia cells lines such as U937 and HL-60.175,176 These
observations strongly suggest that one may optimize the antileuke-
mic activity of anthracyclines by combining them with Apo-2
ligand treatment.
Role of p53 and cyclin kinases in
anthracycline-induced cytotoxicity
Previous studies have shown that doxorubicin, as many other
DNA-damaging agents, activates p53-DNA binding.177 On the
basis of the crucial role of p53 in the execution of some forms of
apoptosis, it has been therefore speculated that p53 could play an
important function in anthracycline cytotoxicity. In fact, the
requirement for wild-type p53 for apoptosis after doxorubicin
exposure has been demonstrated in rodent normal or minimally
transformed ﬁbroblasts and lymphocytes.178,179 However, the role
of p53 mutations in drug-induced apoptosis and cytotoxicity in
human tumor cells is much less clear (see Brown and Wouters for
review180). As far as leukemic cells are concerned, it should be
noted that mostAML cell lines displayed mutated or deleted forms
of p53, including U937 or HL-60 cells, which exhibit high
sensitivity to DNR. This observation suggests that p53 plays a
minor role in anthracycline-induced cytotoxicity in AML cells.
However, some clinical studies have shown that p53 mutations
predictpoorclinicaloutcomeinpatientstreatedwithanthracycline-
containing regimens for hematologic neoplasias such as AML or
large cell non-Hodgkin malignant lymphomas.181,182 It is therefore
possible that loss of p53 function correlates with other drug
resistance mechanisms or interferes with other apoptotic pathways.
In this perspective, it is important to note that wild-type p53 is
necessary for c-Myc–mediated facilitation of doxorubicin-induced
apoptosis.183
Besides its role in apoptosis, p53 plays an important function in
regulating cell cycle transition in doxorubicin-treated cells. Indeed,
it has been shown that doxorubicin-induced p53 activation contrib-
utes to the induction of the WAF1/CIP1 p21 gene product, which is
a strong inhibitor of cyclin-dependent kinases involved in G1 to S
transition.184 Although p53-independent doxorubicin-induced
WAF1/CIP1 has been described,185,186 this mechanism may account
for G1 block after anthracycline exposure in p53 proﬁcient cells. It
has been suggested that WAF1 expression protects cells from
doxorubicin-induced cytotoxicity because G1 block facilitates
complete repair of DNA damage before the cells undergo DNA
replication. In fact, it has been shown that high levels of constitu-
tive WAF1/CIP1 protein are associated with chemoresistance
inAML.187
Other cell cycle alterations have been described in doxorubicin-
treated cells. Indeed, depending on the dose and cellular model,
anthracyclines as many other genotoxic agents may also induce
G2-M block because of p34cdc2 kinase inhibition. Indeed, previ-
ous studies have shown that doxorubicin prevented p34cdc2
dephosphorylationthroughacdc25-independentmechanism,result-
ing in alteration of p34cdc2/cyclin B1-mediated complex.188 The
mechanism by which anthracyclines interfere with p34cdc2 func-
tion has not been carefully examined. However, Kharbanda and
coworkers189,190 have shown that most DNA damaging agents,
including cytosine arabinoside, mitomycin C, and ionizing radia-
tion, induce activation of p56/p53lyn, a tyrosine kinase of the Src
family, which, in turn, phosphorylates and inactivates p34Cdc2.
Whether or not Lyn is involved in anthracycline-induced p34cdc2
kinase inhibition and subsequent G2-M block should be conﬁrmed.
Role of extracellular matrix proteins in
anthracycline-induced cytotoxicity
It is now admitted that the extracellular matrix (ECM) plays an
important role in cell proliferation and survival through a complex
network of signals regulating cytoplasmic kinases, growth factor
receptors, and ion channels.191 In another study, it has been
demonstrated that b1-integrin–mediated adhesion to ECM proteins
protects tumor epithelial cells from doxorubicin-induced apopto-
sis.192This study also provides strong evidence that ECM-activated
outside-in signals involve caspase inhibition through a protein
tyrosine kinase mechanism, whereas adhesion to ECM does not
inﬂuence DNA damage.192 In another study, it has been reported
that myeloma cells adhered to ﬁbronectin, a predominant compo-
nent of ECM, have a survival advantage over nonadhered cells
after doxorubicin exposure.193 The fact that ECM adhesion offers
protection against anthracyclines may have important implications
in other clinical settings. Indeed, it has been documented that both
normal and leukemic myeloid progenitors strongly interact with
ECM in the bone marrow and that b1-integrins play a predominant
role in this process.194 Therefore, it is possible that contact with
ECM contributes signiﬁcantly to the natural chemoresistance of
immature hematopoietic cells. Moreover, it cannot be excluded that
anthracyclines activate inside-out signals, which modulate stem
cell/ECM interactions, and, for example, facilitate the mobilization
of progenitor subsets from the bone marrow to the peripheral
circulation. This possibility could explain the efﬁcacy of anthracy-
cline-contained regimens used for CD341 cell mobilization before
peripheral stem cell transplantation. Of course, the role of ECM
relative to intracellular antiapoptotic pathways is at pres-
ent unknown.
Summary and conclusion
It is evident from these investigations that apoptosis induced by
DNR brings into play a complex network of coordinated and highly
controlled events.Although the characterizations of these different
signaling pathways are still incomplete, we can at present attempt
to concisely recapitulate (with a little speculation) as to the
individual implication of these signaling pathways and mediators
in DNR-induced cell signaling (Figure 1).
Present knowledge suggests that in drug-sensitive cells clini-
cally relevant concentrations of DNR trigger within minutes the
generation of ROS that leads to a ﬁrst wave of N-SMase activation,
sphingomyelin hydrolysis, and consequently CER generation. This
process makes the initial ROS burst the rate-limiting step in
DNR-induced apoptosis signaling, and one can consider these early
events (within the ﬁrst 5 minutes) as the primary apoptotic
initiation step. Then follows a cyclical cascade of ROS-dependent
N-SMase activation and CER generation that perpetuates for about
4 hours until the apoptotic execution steps (caspase activation,
mitochondrial depolarization, etc) come into play. It remains to be
clearly determined, however, whether these cyclical events (which
are p53-independent) are critical in the apoptotic signaling process.
For example, does the inhibition of continual CER or ROS
production signiﬁcantly affect DNR-induced apoptosis (as is
suggested by studies in which the overexpression of Bcl2 [thereby
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generation)? The ROS-dependent sphingomyelin-CER pathway
has been shown to be responsible for rapid activation of the
MEKK1-SEK1-JNK cascade leading to enhanced DNA binding
activity of the transcription factor AP-1. This latter pathway
appears essential in DNR-triggered apoptosis. Of course, all of
these events are absent in drug-resistant cells, and the literature
proposes several potential mechanisms such as rapid CER metabo-
lism into other lipid products (such as sphingosine-1-phosphate or
glucosylceramide) that possess survival/proliferative properties.
However, it remains to be determined to what extent (eg, which is
dominant?) these metabolic events play a role in DNR resistance of
myeloid leukemic cells.
Remarkably, in drug-sensitive cells, DNR also triggers path-
ways that should negatively regulate apoptosis. In parallel, a
phospholipase C–dependent DAG/raf-1/MEK cascade leading to
activation of the transcription factor NF-kB and a DAG-
independent PI3K/PKCz cascade play a signiﬁcant role in cellular
protection. Inhibition (pharmacologically or genetically) of one or
more of these mediators signiﬁcantly increases the apoptotic
response to DNR. One can, of course, speculate that these
“survival” pathways are overridden by the CER pathway in
sensitive cells but are predominant in resistant cells because the
CER pathway is effectively down-regulated. But it appears obvious
that more research is needed to better understand the relationship
between both proapoptotic and antiapoptotic pathways triggered by
DNR (interdependency, cross-talk, degree to which they occur in
dose-dependent studies, and, of course, their relevance in normal
myeloid cells). Finally, the emerging data on gene induction by
anthracyclines, based on cDNA microarray technology, raise the
question of not only the role of these genes (such as DNA-damage-
response genes, eg, GADD) in cell resistance but also the link
between such gene induction and the above-mentioned drug-
triggered signaling pathways.195,196
In conclusion, we now know that DNR triggers both positive
and negative regulatory pathways of apoptosis; therefore, it is now
essential to discriminate among resistance mechanisms of AML
cells: those that lead to decreased drug-target interactions and those
that interfere with cell death commitment. It will also most
certainly be of great importance to delineate the role of effector-
induced cell damage in programmed cell death signaling, and it
will also be necessary to determine if the discrimination between
apoptosis and necrosis is an essential phenomenon for in vivo
therapeutics. Finally, this review incites for a reinterpretation of the
actions of well-established therapeutic agents in the light of recent
advancesinthebasicsciencesthatshouldallowcellularpharmacol-
ogy of antineoplastic agents to continue gathering momentum in
the perspective of overcoming drug resistance by deﬁning pharma-
cologic strategies capable of sensitizing resistant tumor cells and/or
protecting normal physiologic cells to DNR.197
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Erratum
In the article by Stirewalt et al entitled “FLT3, RAS, and TP53 mutations in
elderly patients with acute myeloid leukemia,” which appeared in the June 1,
2001, issue of Blood (Volume 97:3589-3595), the afﬁliations note should
have read “From the Clinical Research Division, Fred Hutchinson Cancer
Research Center, and the Division of Oncology, University of Washington,
Seattle, Washington; Southwest Oncology Group Statistical Center, Seattle,
WA; Southwest Oncology Group Leukemia Biology/Cytogenetic Programs,
San Antonio, TX; Department of Cytogenetics, City of Hope Medical Center,
Duarte, CA; and Department of Pathology and Cell Biology, University of
New Mexico School of Medicine,Albuquerque, NM.”
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